#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hepatitis B Measles Retinopathy of prematurity Immune-mediated renal disorder Anti-neutrophil cytoplasmic antibody positive vasculitis Metastases to peritoneum ABO haemolytic disease of newborn Arteriosclerosis Desmoplastic small round cell tumour Paraneoplastic neurological syndrome Bronchiolitis Cystic fibrosis lung Follicle centre lymphoma follicular grade I, II – III Chronic cutaneous lupus erythematosus Immunodeficiency More trials…

    Learn about Rare Diseases

    Advanced systemic mastocytosis – Life with Disease Rett syndrome – Treatment Congenital hypotransferrinaemia – Treatment Atypical teratoid/rhabdoid tumour of CNS – Life with Disease Primary hyperoxaluria – Treatment Primary immunodeficiency syndrome X-linked lymphoproliferative syndrome – Basic Information Waldenstrom’s macroglobulinaemia recurrent – Basic Information Chronic granulomatous disease – Trials in Disease Primary immunodeficiency syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Methohexital Sodium Gallium (68Ga) Gozetotide Poloxamer 407 Ag-946 Phosphate Fluciclovine (18F) Kyv-101 Nedosiran Arrhenatherum Elatius Thiocolchicoside Temocillin Sodium Prucalopride IPN01195 Sulfamethoxazole Regadenoson Pegcetacoplan Hydroxychloroquine Sulfate H2-Receptor Antagonists RO7837195 Pegvaliase Eteplirsen More therapies…

    Learn about Your Condition

    Hot flush Nephropathy Mixed dementia Embolism venous Post procedural infection Wolfram syndrome Melanoma recurrent Fibromyalgia Post-traumatic headache Binge eating Acute cardiac event Thrombolysis Synovial sarcoma metastatic Haematological malignancy Extra-osseous Ewing's sarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Oscar Lambret

Centre Oscar Lambret

3 Rue Frederic Combemale, Lille, 59000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Sequential Treatment with Gemcitabine, Paclitaxel, and FOLFIRINOX for Patients with Locally Advanced Pancreatic Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma
    Investigated Drugs:
    • Fluorouracil
    • Gemcitabine
    • Irinotecan Hydrochloride Trihydrate
    France

  • Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Endometrial cancer
    • Fallopian tube cancer
    Investigated Drugs:
    • Olaparib
    Belgium Bulgaria Czechia France Germany Hungary +6

  • Study on Continuing or Stopping Imatinib in Patients with Advanced or Metastatic Gastrointestinal Stromal Tumors After 10 Years of Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastrointestinal stromal tumour
    Investigated Drugs:
    • Imatinib Mesilate
    France

  • Study on Retinoblastoma Treatment Using Etoposide, Carboplatin, and Melphalan for Patients with Specific Eye Conditions

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Retinoblastoma
    Investigated Drugs:
    • Carboplatin
    • Etoposide
    • Melphalan
    France

  • Study on Indocyanine Green for Reducing Leakage in Colorectal Cancer Surgery Patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Indocyanine Green
    France

  • Study on Stopping or Continuing Anastrozole, Letrozole, and Exemestane for Patients with Advanced or Metastatic Low-Grade Endometrial Stromal Sarcoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • Study on Hyperthermic Intraperitoneal Chemotherapy with Cisplatin for Patients with Recurrent Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian epithelial cancer
    Investigated Drugs:
    • Cisplatin
    France

  • Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Cyclophosphamide
    Austria Belgium Czechia Finland France Germany +4

  • Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Camizestrant
    Austria Bulgaria Czechia France Germany Hungary +4

  • Study of Pembrolizumab with Etoposide and Cisplatin for First-Line Treatment in Patients with Small Cell Ovarian Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Cisplatin
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    France
Previous Page
1 … 4 5 6 7 8 … 26
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!